CLINICAL TRIAL

Hydroxychloroquine for Breast Cancer

1 Prior Treatment
Recurrent
Recruiting · 18+ · All Sexes · Philadelphia, PA

This study is evaluating whether a combination of two drugs may help prevent cancer from returning in individuals who have completed primary therapy for breast cancer.

See full description

About the trial for Breast Cancer

Eligible Conditions
Stage IIB Breast Cancer · Breast Neoplasms

Treatment Groups

This trial involves 4 different treatments. Hydroxychloroquine is the primary treatment being studied. Participants will be divided into 4 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Experimental Group 1
Hydroxychloroquine
DRUG
Experimental Group 2
Everolimus
DRUG
+
Hydroxychloroquine
DRUG
Experimental Group 3
Everolimus
DRUG
Show More

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Everolimus
FDA approved
Hydroxychloroquine
FDA approved

Eligibility

This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Breast Cancer or the other condition listed above. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
fluorescent-antibody technique The text is discussing a method of testing for a particular receptor in order to determine a person's risk status for a disease show original
are associated with a worse prognosis than histologically negative nodes show original
and 1-3 cm in size A primary tumor that is ER/PR/Her2 negative and 1-3 cm in size is not as likely to spread and is easier to treat. show original
and clean bone marrow A bone marrow aspirate after completion of therapy demonstrates detectable DTCs (via IHC) and clean bone marrow. show original
Age ≥ 18 years
A woman who is diagnosed with early stage breast cancer and has a primary tumor that is estrogen receptor (ER+) positive/HER2 negative and no lymph node involvement as assessed by a physical examination or imaging studies, has a Breast Cancer Recurrence Score (BCRS) of 25 or higher on the Genomic Health Oncotype DX Breast Cancer Test, and does not have evidence of distant metastasis, is considered to have a high risk of recurrence. show original
Some women who have neoadjuvant chemotherapy for breast cancer still have evidence of residual disease in their breasts when they have their surgery show original
Patients must have finished their primary therapy (definitive surgery, adjuvant radiation therapy, and/or herceptin therapy) for their index cancer four weeks prior to study entry show original
There is no evidence of recurrent cancer in the breasts, as shown by physical examination, blood tests, and imaging. show original
This study looked at breast cancer that had been confirmed by a histology test and that had originated from the breast (primary), and that had been diagnosed within 5 years of study entry. show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 3 years
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 3 years.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Hydroxychloroquine will improve 1 primary outcome in patients with Breast Cancer. Measurement will happen over the course of 3 years.

Number of Adverse Events
3 YEARS
3 YEARS

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people get breast cancer a year in the United States?

According to estimates from the 2004 SEER database (SEER 2004), about 1 in 4 women in the United States will have [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) at some point in their life. This accounts for more than 1 in 5 breast cancer deaths, which is the second leading cause of cancer-related mortality in the United States.

Anonymous Patient Answer

What is breast cancer?

The majority of new cases of breast cancer are diagnosed in developed countries, and in industrialized countries, the incidence of breast cancer has continued to increase steadily in the last four decades. This increase is greatest in white women of average age and older. The age of breast cancer patients at diagnosis has not changed significantly for the last four decades.

Anonymous Patient Answer

What causes breast cancer?

Genetic predisposition does not cause [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer). Most women whose breast cancers do not have identifiable causes of onset are not at increased risk of breast cancer. Genetic testing is not routinely performed in women diagnosed with early onset breast cancer. Women diagnosed with breast cancer are usually not screened before the onset of symptoms. Many women presenting with breast cancer are newly diagnosed with metastatic disease. It is unlikely that any type of preventive behavior will change the cancer burden in the population.

Anonymous Patient Answer

Can breast cancer be cured?

The data suggest that the presence of synchronous or distant metastatic disease at the time of diagnosis, high grade histological grade or lack of hormone-receptor/HER2 expression, are independent contraindication against breast cancer cure.

Anonymous Patient Answer

What are common treatments for breast cancer?

Treatment options are often based on tumor stage, grade, and other pathologic features. Treatment options include surgical removal of the lump as part of the initial assessment, surgical removal of the lump when it is determined that the patient has an aggressive cancer, hormonal treatment, and adjuvant therapy for some aggressive cancers.

Anonymous Patient Answer

What are the signs of breast cancer?

Signs are nonspecific because they are usually accompanied by symptoms. Thus, clinical signs are useful for guiding workups and treatment. The signs of breast cancer include persistent or increased nipple, nipple discharge, skin change or discharge (reddened skin), and palpable mass or lump. Breast cancer may be detected and treated through screening or mammography. Appropriate follow up after screening and treatment is necessary because some signs may persist in the future.

Anonymous Patient Answer

Does breast cancer run in families?

A positive association was found between risk of breast cancer and family history of breast cancer. Women in families have a slightly higher risk of developing BC in their lifetime than women without a family history of breast cancer.

Anonymous Patient Answer

How serious can breast cancer be?

Cancer is often thought of as a disease which may not be fatal; however, survival from [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) has improved in recent years in accordance with improvements in treatment of other primary cancers.

Anonymous Patient Answer

What is the latest research for breast cancer?

There were a number of new advances in breast cancer diagnosis and/or treatment but the quality of evidence in support of these is low in most cases. As we discover more about breast cancer it will be possible to see a more consistent pattern of evidence and we expect that the evidence base for breast cancer therapies will eventually stabilise at a level comparable to that of treatment for common conditions such as heart attack or stroke. [http://www.bcbreastcancer.org/?pages=symptom.html#symptom http://www.bcbreastcancer.

Anonymous Patient Answer

Who should consider clinical trials for breast cancer?

There are certain subgroups of breast cancer patients who benefit from clinical trials at the time of diagnosis and also during adjuvant treatment. Clinicians must consider patient factors during the breast cancer workup, identify patients who will most likely benefit from clinical trials and offer them to them.

Anonymous Patient Answer

What are the common side effects of hydroxychloroquine?

The most common side effects of hydroxychloroquine are the common side effects of all cholinesterase inhibitors. These drug-related symptoms have been demonstrated in the studies published by other authors as well. Hydroxychloroquine (10 mg) is usually taken once a day, but in the studies performed by Naggs et al. (2006) and Tingana and Dominguez (2008), hydroxychloroquine was administered in three different doses (10, 20 and 40 mg) and the most common side effects were insomnia, nausea, constipation and fatigue. Other drug-related complaints include: pruritus, sweating, dizziness and dry or itchy skin.

Anonymous Patient Answer

How does hydroxychloroquine work?

Hydroxychloroquine inhibits the replication of HIV-1 in patients after a subtherapeutic dosage of the drug. The mechanism of this effect, however, appears to be complex and more research is needed.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Breast Cancer by sharing your contact details with the study coordinator.